The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa

被引:12
|
作者
Jamieson, Lise [1 ,2 ]
Gomez, Gabriela B. [3 ]
Rebe, Kevin [4 ]
Ben Brown [4 ]
Subedar, Hasina [5 ]
Jenkins, Sarah [6 ]
Shoko, Natsai [7 ]
Bekker, Linda-Gail [8 ]
Johnson, Leigh F. [9 ]
Meyer-Rath, Gesine [1 ,2 ,10 ]
机构
[1] Hlth Econ & Epidemiol Res Off HE2RO, Johannesburg, South Africa
[2] Univ Witwatersrand, Fac Hlth Sci, Dept Med, Johannesburg, South Africa
[3] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Global Hlth & Dev, London, England
[4] ANOVA Hlth Inst, Cape Town, South Africa
[5] Natl Dept Hlth, Pretoria, South Africa
[6] Clinton Hlth Access Initiat, Philadelphia, PA USA
[7] Clinton Hlth Access Initiat, Pretoria, South Africa
[8] Univ Cape Town, Desmond Tutu HIV Ctr, Cape Town, South Africa
[9] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, Cape Town, South Africa
[10] Boston Univ, Sch Publ Hlth, Dept Global Hlth, Boston, MA USA
基金
美国国家卫生研究院;
关键词
cost; cost-effectiveness analysis; high-risk populations; preexposure prophylaxis; South Africa; HETEROSEXUAL MEN; PREVENTION; INFECTION; WOMEN; TRANSMISSION; COUPLES;
D O I
10.1097/QAD.0000000000002486
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: We explored the impact and cost-effectiveness of preexposure prophylaxis (PrEP) provision to different populations in South Africa, with and without effective self-selection by individuals at highest risk of contracting HIV (through concurrent partnerships and/or commercial sex). Design and methods: We used a previously developed HIV transmission model to analyse the epidemiological impact of PrEP provision to adolescents, young adults, pregnant women, female sex workers (FSWs) and (MSM), and data from South African PrEP programmes to estimate the cost and cost-effectiveness of PrEP (cost in 2019 USD per HIV infection averted over 20 years, 2019, 38). PrEP uptake followed data from early implementation sites, scaled-up linearly over 3 years, with target coverage set to 18% for adolescents, young adults and pregnant women, 30% for FSW and 54% for MSM. Results: The annual cost of PrEP provision ranges between $75 and $134 per person. PrEP provision adolescents and young adults, regardless of risk behaviour, will each avert 3.2--4.8% of HIV infections over 20 years; provision to high-risk individuals only has similar impact at lower total cost. The incremental cost per HIV infection averted is lower in high-risk vs. all-risk sub-populations within female adolescents ($507 vs. $4537), male adolescents ($2108 vs. $5637), young women ($1592 vs. $10 323) and young men ($2605 vs. $7715), becoming cost saving within 20 years for high-risk adolescents, young women, MSM and FSWs. Conclusion: PrEP is an expensive prevention intervention but uptake by those at the highest risk of HIV infection will make it more cost-effective, and cost-saving after 14-18 years.
引用
收藏
页码:883 / 891
页数:9
相关论文
共 50 条
  • [1] Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa
    Glaubius, Robert L.
    Hood, Greg
    Penrose, Kerri J.
    Parikh, Urvi M.
    Mellors, John W.
    Bendavid, Eran
    Abbas, Ume L.
    CLINICAL INFECTIOUS DISEASES, 2016, 63 (04) : 539 - 547
  • [2] HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness
    Paltiel, A. David
    Freedberg, Kenneth A.
    Scott, Callie A.
    Schackman, Bruce R.
    Losina, Elena
    Wang, Bingxia
    Seage, George R., III
    Sloan, Caroline E.
    Sax, Paul E.
    Walensky, Rochelle P.
    CLINICAL INFECTIOUS DISEASES, 2009, 48 (06) : 806 - 815
  • [3] Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States
    Leech, Ashley A.
    Burgess, James F.
    Sullivan, Meg
    Kuohung, Wendy
    Horny, Michal
    Drainoni, Mari-Lynn
    Christiansen, Cindy L.
    Linas, Benjamin P.
    AIDS, 2018, 32 (18) : 2787 - 2798
  • [4] Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States A Cost-Effectiveness Analysis
    Neilan, Anne M.
    Landovitz, Raphael J.
    Le, Mylinh H.
    Grinsztejn, Beatriz
    Freedberg, Kenneth A.
    McCauley, Marybeth
    Wattananimitgul, Nattanicha
    Cohen, Myron S.
    Ciaranello, Andrea L.
    Clement, Meredith E.
    Reddy, Krishna P.
    Hyle, Emily P.
    Paltiel, A. David
    Walensky, Rochelle P.
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (04) : 479 - +
  • [5] The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa
    Walensky, Rochelle P.
    Wood, Robin
    Fofana, Mariam O.
    Martinson, Neil A.
    Losina, Elena
    April, Michael D.
    Bassett, Ingrid V.
    Morris, Bethany L.
    Freedberg, Kenneth A.
    Paltiel, A. David
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 (01) : 26 - 35
  • [6] Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States
    Bernard, Cora L.
    Brandeau, Margaret L.
    Humphreys, Keith
    Bendavid, Eran
    Holodniy, Mark
    Weyant, Christopher
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    ANNALS OF INTERNAL MEDICINE, 2016, 165 (01) : 10 - +
  • [7] The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India
    Kazemian, Pooyan
    Costantini, Sydney
    Kumarasamy, Nagalingeswaran
    Paltiel, A. David
    Mayer, Kenneth H.
    Chandhiok, Nomita
    Walensky, Rochelle P.
    Freedberg, Kenneth A.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (04) : 633 - 642
  • [8] Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness
    Bassett, Ingrid V.
    Govindasamy, Darshini
    Erlwanger, Alison S.
    Hyle, Emily P.
    Kranzer, Katharina
    van Schaik, Nienke
    Noubary, Farzad
    Paltiel, A. David
    Wood, Robin
    Walensky, Rochelle P.
    Losina, Elena
    Bekker, Linda-Gail
    Freedberg, Kenneth A.
    PLOS ONE, 2014, 9 (01):
  • [9] IMPLICATIONS OF PATIENT SELF-SELECTION FOR PREFERENCE ELICITATION FOR COST-EFFECTIVENESS ANALYSIS
    Meltzer, David O.
    Huang, Elbert
    Brown, Sydney
    Zhang, Qi
    QUALITY OF LIFE RESEARCH, 2005, 14 (09) : 2113 - 2113
  • [10] Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa
    Alistar, Sabina S.
    Grant, Philip M.
    Bendavid, Eran
    BMC MEDICINE, 2014, 12